Adjuvant capecitabine in combination with docetaxel, epirubicin, and cyclophosphamide for early breast cancer the randomized clinical finxx trial

JAMA Oncology

Volumn 3, Issue 6, 2017, Pages 793-800

  Joensuu, Heikki ^a   Kellokumpu Lehtinen, Pirkko Liisa ^b   Huovinen, Riikka ^c   Jukkola Vuorinen, Arja ^d   Tanner, Minna ^b   Kokko, Riitta ^e   Ahlgren, Johan ^f   Auvinen, Päivi ^g   Lahdenperä, OutiMD ^c   Kosonen, Sanna ^h   Villman, Kenneth ⁱ   Nyandoto, Paul ^j   Nilsson, Greger ^k   Poikonen Saksela, Paula ^a   Kataja, Vesa ^g,l   Junnila, Jouni ^m   Bono, Petri ^a   Lindman, Henrik ^k  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c TURKU UNIVERSITY HOSPITAL   (Finland)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e KANTA HÄME CENTRAL HOSPITAL   (Finland)

^f GÄVLE HOSPITAL   (Sweden)

^g KUOPIO UNIVERSITY HOSPITAL   (Finland)

^h Kotka Central Hospital   (Finland)

ⁱ ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^j PÄIJÄT HÄME CENTRAL HOSPITAL   (Finland)

^k UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^l VAASA CENTRAL HOSPITAL   (Finland)

^m 4Pharma ^*  (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; PROGESTERONE RECEPTOR; TAXOID;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; EPIDEMIOLOGY; FEMALE; FINLAND; HUMAN; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAPECITABINE; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; EPIRUBICIN; FEMALE; FINLAND; FLUOROURACIL; HUMANS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SWEDEN; TAXOIDS; TREATMENT OUTCOME; TRIPLE NEGATIVE BREAST NEOPLASMS; YOUNG ADULT;

EID: 85025064457     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.6120     Document Type: Article

References (28)

1. Miwa M, Ura M, Nishida M., et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer. 1998; 34(8):1274-1281.
2. Endo M, Shinbori N, Fukase Y., et al. Induction of thymidine phosphorylase expression and enhancement of efficacy of capecitabine or 5'-deoxy-5-fluorouridine by cyclophosphamide in mammarytumor models. Int JCancer. 1999; 83(1): 127-134.
3. Fujimoto-Ouchi K., Tanaka Y, Tominaga T. Schedule dependency of antitumor activity in combination therapy with capecitabine/5'-deoxy-5 -fluorouridine and docetaxel in breast cancer models. Clin Cancer Res. 2001; 7(4):1079-1086.
4. O'Shaughnessy J., Miles D, Vukelja S., et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol. 2002; 20(12):2812-2823.
5. Campone M, Dobrovolskaya N, Tjulandin S., et al. A three-arm randomized phase II study of oral vinorelbine plus capecitabine versus oral vinorelbine and capecitabine in sequence versus docetaxel plus capecitabine in patients with metastatic breast cancer previously treated with anthracyclines. Breast J. 2013; 19(3):240-249.
6. Wardley AM, Pivot X, Morales-Vasquez F, et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol. 2010; 28(6): 976-983.
7. O'Shaughnessy J., Koeppen H, Xiao Y., et al. Patients with slowly proliferative early breast cancer have low five-year recurrence rates in a phase III adjuvant trial of capecitabine. Clin Cancer Res. 2015; 21(19):4305-4311.
8. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R., et al; FinXX Study Investigators. Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for breast cancer: an open-label, randomised controlled trial. Lancet Oncol. 2009; 10(12):1145-1151.
9. Joensuu H, Kellokumpu-Lehtinen PL, Huovinen R., et al. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. J Clin Oncol. 2012; 30(1):11-18.
10. Muss HB, Berry DA, Cirrincione C.T., et al; CALGB Investigators. Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009; 360(20):2055-2065.
11. Kelly CM, Green MC, Broglio K, et al Phase III trial evaluating weekly paclitaxel versus docetaxel in combination with capecitabine in operable breast cancer. J Clin Oncol. 2012; 30(9):930-935.
12. von Minckwitz G., Conrad B, Reimer T., et al; German Breast Group Investigators. A randomized phase 2study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52). Cancer. 2015; 121(20):3639-3648.
13. Martín M., Ruiz Simón A, Ruiz Borrego M, et al. Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: results from the GEICAM/2003-10 study. J Clin Oncol. 2015; 33(32): 3788-3795.
14. Toi M, Lee S-J, Lee ES, et al A phase III trial of adjuvant capecitabine in breast cancer patients with HER2-negative pathologic residual invasive disease after neoadjuvant chemotherapy (CREATE-X, JBCRG-04). From the 38th Annual San Antonio Breast Cancer Symposium, December 8-12, 2015, San Antonio, TX (abstract S1-07). https://www.sabcs.org. Accessed December 6, 2016.
15. Zhimin S, Li J, Pang D., et al. Cbcsg-10: Adjuvant capecitabine in combination with docetaxel and cyclophosphamide plus epirubicin for triple negative breast cancer [abstract 1012]. http://meetinglibrary.asco.org/content/163338-176. Accessed December 5, 2016.
16. Steger GG, Greil R, Lang A., et al; Austrian Breast and Colorectal Study Group (ABCSG). Epirubicin and docetaxel with or without capecitabine as neoadjuvant treatment for early breast cancer: final results of a randomized phase III study (ABCSG-24). Ann Oncol. 2014; 25(2):366-371.
17. von Minckwitz G., Rezai M, Loibl S., et al. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol. 2010; 28(12):2015-2023.
18. von Minckwitz G., Rezai M, Fasching P.A., et al. Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40 - GeparQuattro). Ann Oncol. 2014; 25(1):81-89.
19. Bear HD, Tang G, Rastogi P., et al. Bevacizumab added to neoadjuvant chemotherapy for breast cancer. N Engl J Med. 2012; 366(4):310-320.
20. Bear HD, Tang G, Rastogi P., et al. Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncol. 2015; 16(9):1037-1048.
21. Myers RE, Johnston M, Pritchard K., Levine M, Oliver T; Breast Cancer Disease Site Group of the Cancer Care Ontario Practice Guidelines Initiative. Baseline staging tests in primary breast cancer: a practice guideline. CMAJ. 2001; 164(10):1439-1444.
22. Ravaioli A, Pasini G, Polselli A., et al. Staging of breast cancer: new recommended standard procedure. Breast Cancer Res Treat. 2002; 72(1):53-60.
23. Bonilla L, Ben-Aharon I, Vidal L., Gafter-Gvili A, Leibovici L, Stemmer SM Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials. J Natl Cancer Inst. 2010; 102(24):1845-1854.
24. Petrelli F, Cabiddu M, Coinu A., et al. Adjuvant dose-dense chemotherapy in breast cancer: a systematic review and meta-analysis of randomized trials. Breast Cancer Res Treat. 2015; 151 (2):251-259.
25. Schilsky RL. Biochemical and clinical pharmacology of 5-fluorouracil. Oncology (Williston Park). 1998; 12(10)(suppl 7):13-18.
26. Cancer Genome Atlas Network. Comprehensive molecular portraitsofhuman breast tumours. Nature. 2012; 490(7418):61-70.
27. Hammond ME, Hayes DF, Dowsett M, et al; American Society of Clinical Oncology; College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010; 134(7):e48-e72.
28. Prabhu JS, Korlimarla A, Desai K., et al. A majority of low (1-10%) ER positive breast cancers behave like hormone receptor negative tumors. J Cancer. 2014; 5(2):156-165.